Highlights from AUA2025: Advances in NMIBC (2025)

CME Available: https://auau.auanet.org/node/43167

At the conclusion of this CME activity, participants will be able to:

1. Recognize recent developments in the management of NMIBC.

2. Evaluate new and emerging therapies for NMIBC, such as novel intravesical agents and immunotherapies, their mechanism of action and related adverse events.

3. Employ current management approaches for NMIBC.

4. Utilize risk stratification to guide treatment decisions for NMIBC patients.

5. Implement diagnostic techniques for NMIBC, including cystoscopy, urine cytology, biomarkers, and advanced imaging modalities.

This educational activity is supported by independent educational grants from:

Merck & Co., Inc.

ImmunityBio, Inc.